Please assess the completion status of the following clinical trial:

Trial Title: Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥18 years of age at the time of the screening visit~2. Diagnosis of HeFH (Heterozygous familial hypercholesterolemia)~3. Currently undergoing LDL (low-density lipoprotein) apheresis therapy QW (weekly) or Q2W (every 2 weeks) or at least 8 weeks prior to the screening visit~Exclusion Criteria:~1. Homozygous FH (familial hypercholesterolemia)~2. Background medical LMT (lipid-modifying therapy) (if applicable) that has not been stable for at least 8 weeks prior to the screening visit~3. LDL apheresis schedule/ apheresis settings that have not been stable for at least 8 weeks prior to the screening visit~4. An LDL apheresis schedule other than QW to Q2W~5. Initiation of a new exercise program or exercise that has not remained stable within 8 weeks prior to the screening visit (week -2)~6. Initiation of a new diet or a diet that has not been stable within 8 weeks prior to the screening visit (week -2)~7. Use of nutraceuticals or over-the-counter therapies known to affect lipids, at a dose/amount that has not been stable for at least 8 weeks prior to the screening visit (week -2), or between the screening and randomization visit~8. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins~9. Known history of a positive test for human immunodeficiency virus~10. Use of any active investigational drugs within 1 month or 5 half-lives of screening, whichever is longer~11. Patients who have been treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in any other clinical studies~12. Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Double Blind Period) (Type: EXPERIMENTAL): Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
- Alirocumab 150 mg Q2W (Double Blind Period) (Type: EXPERIMENTAL): Alirocumab 150 mg SC injection Q2W up to Week 16.
- Alirocumab 150 Q2W (Open Label Treatment Period) (Type: EXPERIMENTAL): Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.

Based on this trial design, predict the completion outcome and termination type (if applicable).